Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

by Ramchandren, Radhakrishnan , Campana, Frank , Eom, Hyeon-Seok , Fenton, Keenan , Straus, David J. , Evens, Andrew M. , Radford, John , Friedberg, Jonathan W. , Advani, Ranjana , Savage, Kerry J. , Abramson, Jeremy S. , Gallamini, Andrea , Puhlmann, Markus , Connors, Joseph M. , Długosz-Danecka, Monika , Kim, Won-Seog , Hutchings, Martin , Ansell, Stephen M. , Bartlett, Nancy L. , Smolewski, Piotr , Dong, Cassie

in Antineoplastic Agents, Immunological - adverse effects / Antineoplastic Agents, Immunological - therapeutic use / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Bleomycin / Bleomycin - administration & dosage / Bleomycin - adverse effects / Brentuximab Vedotin - administration & dosage / Brentuximab Vedotin - adverse effects / CD30 antigen / Chemotherapy / Clinical outcomes / Colony-stimulating factor / Dacarbazine / Dacarbazine - administration & dosage / Dacarbazine - adverse effects / Disease-Free Survival / Doxorubicin / Doxorubicin - administration & dosage / Doxorubicin - adverse effects / Follow-Up Studies / Granulocyte colony-stimulating factor / Hematology / Hodgkin Disease - drug therapy / Hodgkin Disease - mortality / Hodgkin Disease - pathology / Humans / Immunotherapy / Leukemia / Leukocytes (granulocytic) / Lymphoma / Medical prognosis / Monoclonal antibodies / Neoplasm Staging / Neutropenia / Oncology / Patients / Peripheral neuropathy / Prophylaxis / Survival / Survival Analysis / Targeted cancer therapy / Transplantation / Treatment Outcome / Treatments in Oncology / Vinblastine / Vinblastine - administration & dosage / Vinblastine - adverse effects

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

2022

Confirm

Do you wish to request the book?

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

Ramchandren, Radhakrishnan,

Campana, Frank,

Eom, Hyeon-Seok,

Fenton, Keenan,

Straus, David J.,

Evens, Andrew M.,

Radford, John,

Friedberg, Jonathan W.,

Advani, Ranjana,

Savage, Kerry J.,

Abramson, Jeremy S.,

Gallamini, Andrea,

Puhlmann, Markus,

Connors, Joseph M.,

Długosz-Danecka, Monika,

Kim, Won-Seog,

Hutchings, Martin,

Ansell, Stephen M.,

Bartlett, Nancy L.,

Smolewski, Piotr,

Dong, Cassie

2022

Overview

The replacement of bleomycin with the immune drug conjugate brentuximab vedotin in the first-line chemotherapy regimen for advanced Hodgkin’s lymphoma prolonged both progression-free and overall survival.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Antineoplastic Agents, Immunological - adverse effects

/ Antineoplastic Agents, Immunological - therapeutic use

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use

/ Bleomycin

/ Bleomycin - administration & dosage

/ Bleomycin - adverse effects